{"title":"醋酸格拉替默降低心血管疾病和心肌梗死的风险。","authors":"Steven Lehrer, Peter H Rheinstein","doi":"10.21873/invivo.14001","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aim: </strong>The aim of the present study was to investigate on the repurposing of glatiramer acetate (GA), a drug traditionally used to treat multiple sclerosis, as well as explore GA potential to treat cardiac ischemia in rodent models. It has been shown that GA exerts immunomodulatory effects that reduced inflammation and increased repair of heart tissue following myocardial infarction (MI) in mice and rats. GA has been shown to enhance cardiac function by promoting angiogenesis, reducing scar tissue, and protecting cardiomyocytes from ischemic damage.</p><p><strong>Materials and methods: </strong>Risteys/FinnGen and MedWatch/OpenVigil data were used to assess the effects of GA on the heart.</p><p><strong>Results: </strong>There was significantly less ischemic heart disease (p<0.001, Fisher's exact test) and cardiovascular disease (p<0.001) in 457 subjects with MS who used GA in Risteys/FinnGen. Analysis of MedWatch/OpenVigil data showed a significantly reduced risk of acute MI in individuals using GA, with a proportional reporting ratio (PRR) of 0.101, indicating statistical significance at the 95% confidence level. Additionally, analysis of MedWatch/OpenVigil data indicated a decreased risk of cardiovascular disease in GA users, with a PRR of 0.345, reaching statistical significance at the 95% confidence level.</p><p><strong>Conclusion: </strong>Despite rare adverse cardiovascular side-effects and given its established safety profile, GA shows promise as a novel treatment option for heart disease. Further studies could lead to an important new use of GA especially in patients who do not receive tissue plasminogen activator within the first few hours following an MI.</p>","PeriodicalId":13364,"journal":{"name":"In vivo","volume":"39 4","pages":"2066-2072"},"PeriodicalIF":1.8000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223661/pdf/","citationCount":"0","resultStr":"{\"title\":\"Glatiramer Acetate Reduces Risk of Cardiovascular Disease and Myocardial Infarction.\",\"authors\":\"Steven Lehrer, Peter H Rheinstein\",\"doi\":\"10.21873/invivo.14001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background/aim: </strong>The aim of the present study was to investigate on the repurposing of glatiramer acetate (GA), a drug traditionally used to treat multiple sclerosis, as well as explore GA potential to treat cardiac ischemia in rodent models. It has been shown that GA exerts immunomodulatory effects that reduced inflammation and increased repair of heart tissue following myocardial infarction (MI) in mice and rats. GA has been shown to enhance cardiac function by promoting angiogenesis, reducing scar tissue, and protecting cardiomyocytes from ischemic damage.</p><p><strong>Materials and methods: </strong>Risteys/FinnGen and MedWatch/OpenVigil data were used to assess the effects of GA on the heart.</p><p><strong>Results: </strong>There was significantly less ischemic heart disease (p<0.001, Fisher's exact test) and cardiovascular disease (p<0.001) in 457 subjects with MS who used GA in Risteys/FinnGen. Analysis of MedWatch/OpenVigil data showed a significantly reduced risk of acute MI in individuals using GA, with a proportional reporting ratio (PRR) of 0.101, indicating statistical significance at the 95% confidence level. Additionally, analysis of MedWatch/OpenVigil data indicated a decreased risk of cardiovascular disease in GA users, with a PRR of 0.345, reaching statistical significance at the 95% confidence level.</p><p><strong>Conclusion: </strong>Despite rare adverse cardiovascular side-effects and given its established safety profile, GA shows promise as a novel treatment option for heart disease. Further studies could lead to an important new use of GA especially in patients who do not receive tissue plasminogen activator within the first few hours following an MI.</p>\",\"PeriodicalId\":13364,\"journal\":{\"name\":\"In vivo\",\"volume\":\"39 4\",\"pages\":\"2066-2072\"},\"PeriodicalIF\":1.8000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12223661/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"In vivo\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.21873/invivo.14001\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"In vivo","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/invivo.14001","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
Glatiramer Acetate Reduces Risk of Cardiovascular Disease and Myocardial Infarction.
Background/aim: The aim of the present study was to investigate on the repurposing of glatiramer acetate (GA), a drug traditionally used to treat multiple sclerosis, as well as explore GA potential to treat cardiac ischemia in rodent models. It has been shown that GA exerts immunomodulatory effects that reduced inflammation and increased repair of heart tissue following myocardial infarction (MI) in mice and rats. GA has been shown to enhance cardiac function by promoting angiogenesis, reducing scar tissue, and protecting cardiomyocytes from ischemic damage.
Materials and methods: Risteys/FinnGen and MedWatch/OpenVigil data were used to assess the effects of GA on the heart.
Results: There was significantly less ischemic heart disease (p<0.001, Fisher's exact test) and cardiovascular disease (p<0.001) in 457 subjects with MS who used GA in Risteys/FinnGen. Analysis of MedWatch/OpenVigil data showed a significantly reduced risk of acute MI in individuals using GA, with a proportional reporting ratio (PRR) of 0.101, indicating statistical significance at the 95% confidence level. Additionally, analysis of MedWatch/OpenVigil data indicated a decreased risk of cardiovascular disease in GA users, with a PRR of 0.345, reaching statistical significance at the 95% confidence level.
Conclusion: Despite rare adverse cardiovascular side-effects and given its established safety profile, GA shows promise as a novel treatment option for heart disease. Further studies could lead to an important new use of GA especially in patients who do not receive tissue plasminogen activator within the first few hours following an MI.
期刊介绍：
IN VIVO is an international peer-reviewed journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of physiology, pathology and disease management.
The topics of IN VIVO include: 1. Experimental development and application of new diagnostic and therapeutic procedures; 2. Pharmacological and toxicological evaluation of new drugs, drug combinations and drug delivery systems; 3. Clinical trials; 4. Development and characterization of models of biomedical research; 5. Cancer diagnosis and treatment; 6. Immunotherapy and vaccines; 7. Radiotherapy, Imaging; 8. Tissue engineering, Regenerative medicine; 9. Carcinogenesis.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
